Things To Consider Before A Patent Deal With A Tribe

By Matthew Bultman (September 27, 2017, 8:06 PM EDT) -- Following news of Allergan PLC's surprise licensing deal with a Native American tribe, other companies could be considering similar arrangements in hopes of shielding their patents from review at the Patent Trial and Appeal Board. But there may be reasons for pause, experts said.

The Irish drugmaker made waves earlier this month when it sold patents for the eye drug Restasis to the Saint Regis Mohawk tribe in New York and then licensed them back. It contends that as a sovereign nation, the tribe is immune to patent challenges in inter partes review at the Patent Trial and Appeal Board....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!